Breast Cancer

New findings published on treatment for late-stage breast cancer

Published in Health and Medicine Week, April 19th, 2004

A study published in the Journal of Clinical Oncology suggests that targeted therapy for women with HER-2 positive metastatic breast cancer is more effective and less costly when fluorescence in situ hybridization (FISH) technology is used to determine a patient's HER-2 gene status.

The study, a cost-effectiveness model developed by the Harvard University Center for Risk Analysis and School of Public Health, the Dana-Farber Cancer Institute, and Beth Israel Deaconess Medical Center, compared the use of FISH testing alone with its use in confirming the results of immunohistochemistry (IHC) testing to identify candidates for Herceptin (trastuzumab) therapy.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry